Tian Zhang, M.D. Associate Professor School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Tian Zhang, M.D., M.H.S., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology. Dr. Zhang earned her medical degree from the Harvard-MIT Health Sciences and Technology program at Harvard Medical School. She completed a residency in internal medicine at Duke University in North Carolina, where she also received advanced training through a hematology-oncology fellowship. In addition, she earned a Master of Health Sciences in the Clinical Research Training Program at Duke. Certified by the American Board of Internal Medicine in medical oncology, she joined the UT Southwestern faculty in 2021. Dr. Zhang was appointed Associate Director of Clinical Research in the Simmons Comprehensive Cancer Center in May 2024. She also serves as Director of Clinical Research within the Division of Hematology and Oncology in the Department of Internal Medicine. She is an accomplished clinical trialist and translational researcher focused on evaluating the clinical development of novel therapeutics and evaluating biomarkers for genitourinary malignancies. She partners closely with a multidisciplinary team at UT Southwestern to provide data-driven clinical care for her patients. She specializes in the diagnosis and treatment of genitourinary malignancies, including kidney, prostate, bladder, and testicular cancers. Dr. Zhang is a member of several professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research, European Society for Medical Oncology, the Society for Immunotherapy of Cancer (SITC) and the Chinese American Hematology and Oncology Network (CAHON). Dr. Zhang serves on numerous committees, including as Co-chair of the National Cancer Institute Genitourinary Steering Committee Renal Task Force. She is a member of several ASCO and SITC clinical management guidelines committees as well as the Alliance for Clinical Trials in Oncology GU Oncology, and Immuno-Oncology Committees. She brings a track record of research and mentoring to UT Southwestern. She has received multiple peer-reviewed grants, including notably, the 2021 Cancer Prevention & Research Institute of Texas Scholar Rising Stars Award. She is co-PI on several DOD and NCI funded grants. Her laboratory focuses on correlative and biomarker studies for patients with GU cancers. Education Medical School Harvard Medical School (2009) Internship Duke University (2010) Residency Duke University Medical Center (2012), Internal Medicine Fellowship Duke University Medical Center (2015), Hematology Oncology Graduate School Duke University Medical Center (2019) Other Post Graduate Training Duke University School of Medicine (2019) Research Interest Cancer therapies Hematology and Oncology Publications Featured Publications Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma. Bhavsar NA, Harrison MR, Scales CD, Zhang T, Troy J, Ward K, Jabusch SM, Lampron Z, George DJ, Eur Urol Open Sci 2024 Aug 66 75-81 Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer. Holland L, Bhanvadia R, Ibeziako N, Taylor J, Gerlt D, Chaplin I, Bagrodia A, Desai N, Gaston K, Lotan Y, Margulis V, Zhang T, Cole S, Woldu S, Urol Oncol 2024 Jul Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial. Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell BA, Nordquist L, Rasmussen J, Riggan C, Reyes M, Davies C, Gray SR, Newman CR, Fernandez E, Ramalingam S, Harrison MR, George DJ, Wu Y, Armstrong AJ, Eur Urol Oncol 2024 Jul Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation. Moore C, Naraine I, Zhang T, Oncologist 2024 Jun Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma. Gulati S, Barata PC, Elliott A, Bilen MA, Burgess EF, Choueiri TK, Darabi S, Dawson NA, Gartrell BA, Hammers HJ, Heath EI, Magee D, Rao A, Ryan CJ, Twardowski P, Wei S, Brugarolas J, Zhang T, Zibelman MR, Nabhan C, McKay RR, J Clin Invest 2024 May 134 14 Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles. Barata P, Gulati S, Elliott A, Hammers HJ, Burgess EF, Gartrell BA, Darabi S, Bilen MA, Basu A, Geynisman DM, Dawson NA, Zibelman MR, Zhang T, Wei S, Ryan CJ, Heath EI, Poorman KA, Nabhan C, McKay RR, J Clin Invest 2024 Apr Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T, N Engl J Med 2024 Apr 390 15 1359-1371 Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ, JU Open Plus 2024 Apr 2 4 Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ, JU Open Plus 2024 Apr 2 4 Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer. Fecteau RE, Koontz BF, Hoffman KE, Halabi S, Howard LE, Anand M, George DJ, Zhang T, Berry WR, Lee WR, Harrison MR, Corn PG, Armstrong AJ, Prostate Cancer Prostatic Dis 2024 Feb Results 1-10 of 120 1 2 3 4 5 Next Last Honors & Awards Nominee, Women Leaders in Oncology Leadership Award (2022) Cancer Prevention and Research Institute of Texas Scholar Rising Stars Award (2021) Department of Medicine Resident Research Mentoring AwardDuke University (2020) Professional Associations/Affiliations American Association of Cancer Research (2013) American Society for Clinical Oncology (2011) Chinese American Hematologist and Oncologist Network (2019) European Society for Medical Oncology (2017) Society for Immunotherapy of Cancer (2018) Society for the Immunotherapy of Cancer Women in Cancer Immunotherapy Network (2019)
